Results 111 to 120 of about 1,772,527 (156)

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

open access: yesCancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux   +24 more
wiley   +1 more source

Modulation of the RNA‐sensing RIG/MAVS pathway bypasses resistance to hypomethylating agents in acute myeloid leukemia

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract DNA hypomethylating agents (HMAs) such as 5‐azacytidine (5‐AZA) are a cornerstone in the treatment of acute myeloid leukemia (AML), but development of resistance represents a major clinical challenge. Apart from epigenetic reprogramming of malignant cell clones, therapy with HMA is increasingly recognized to facilitate antineoplastic immunity,
Nadia El Khawanky   +20 more
wiley   +1 more source

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study

open access: yesBlood and Lymphatic Cancer: Targets and Therapy
Na Zhao,1,2,* Lijun Zhu,1,* Xing Hu,1,* Juan Tong,1 Hongfeng Ge,3 Li Ye,4 Xijun Zhu,5 Can Gai,6 Yuhu Feng,7 Lei Zhang,1 Li Wang,1 Guangyu Sun,1 Lei Xue,1 Xiaoyu Zhu,1 Changcheng Zheng1,8 1Department of Hematology, the First ...
Zhao N   +14 more
doaj  

Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè   +9 more
wiley   +1 more source

Targeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.
Overcoming chemoresistance in gastric cancer by targeting TLR2. ABSTRACT Chemoresistance remains a major barrier to effective treatment of gastric cancer (GC), particularly in advanced disease, where cytotoxic chemotherapy often yields limited and transient responses.
Kuanheng Zheng   +6 more
wiley   +1 more source

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML

open access: yes
European Journal of Haematology, Volume 117, Issue 6, Page 1671-1675, December 2026.
Shira N. Dinner   +16 more
wiley   +1 more source

Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2148-2159, November 2026.
Summary Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...
Hyunkyung Park   +15 more
wiley   +1 more source

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2160-2167, November 2026.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas   +22 more
wiley   +1 more source

Meta-analysis on hypomethylating agents in myelodysplastic syndromes

open access: yesHaematologica, 2010
Christine Herbst   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy